Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
WARREN, N.J., April 11, 2017 -- MonoSol Rx, a specialty pharmaceutical company leveraging its PharmFilm® technology to develop and bring to market products that improve patient outcomes and address unmet needs, today announced the appointment of James S. Scibetta to the company’s board of directors.
Mr. Scibetta brings a wealth of specialty pharmaceutical industry experience to the MonoSol Rx board of directors. In his current role as President of Pacira Pharmaceuticals (Nasdaq:PCRX), he oversees the day-to-day operations of the Customer and Patient Solutions group, and its commercial activities related to the flagship product EXPAREL®, and also directs the company’s Science Center Campus and UK entity activities related to manufacturing, technology transfer and R&D. From 2008 through May 2016, Mr. Scibetta was CFO, and he led the company’s IPO in 2011. As part of the executive team at Pacira, Mr. Scibetta helped the company transition from a business model centered around royalty-based licensing of a drug delivery technology, into a fully integrated developer of proprietary commercialized products. Mr. Scibetta also serves on the Board of Matinas BioPharma (NYSE:MTNB), a clinical stage specialty pharma company using its proprietary, lipid-crystal, nanoparticle delivery technology to provide oral administration of anti-infective medicines which today are only able to be delivered intravenously,
Before joining Pacira, Mr. Scibetta was CFO of Bioenvision Inc. (Nasdaq:BIVN) where he was instrumental in completing the $345 million sale of the company to Genzyme Corporation, and he was CFO of Merrimack Pharmaceuticals Inc. Additionally, Mr. Scibetta has spent more than a decade in investment banking, where he sourced and executed transactions for a broad base of public and private healthcare and life sciences companies. Mr. Scibetta received his Bachelor of Science in Physics from Wake Forest University and a Master of Business Administration from the University of Michigan.
“Jim offers several decades of knowledge and experience to our company’s board, and his contributions will be important to the company’s continued growth,” said Keith Kendall, CEO of MonoSol Rx. “We look forward to Jim’s added perspective as MonoSol Rx transitions to developing and commercializing its own set of proprietary products. Jim’s experience is a great fit for where we see the future of the company.”
“I am pleased to join the board of directors at MonoSol Rx and look forward to working closely with the board and management team to extend the company’s reach into new market segments,” said James Scibetta, President of Pacira. “The company’s growing portfolio of commercial and development stage products have the potential to offer a better delivery option, underpinned by MonoSol Rx’s best-in class technology, for patients suffering from a variety of diseases.”
About MonoSol Rx
MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm technology to develop products that improve patient outcomes and address unmet needs. PharmFilm can benefit patients by improving the efficacy, safety, and compliance of pharmaceutical products. MonoSol Rx's leadership in film drug technology is supported by strong IP protection, a robust pipeline of prescription drug formulations, and two FDA-approved products — Suboxone® (buprenorphine and naloxone) sublingual film and Zuplenz® (ondansetron) oral soluble film. For press releases and other company information, visit www.monosolrx.com.
Contact MonoSol Rx Jessica Patel [email protected] The Ruth Group Lee Roth [email protected] (646) 536-7012
